RxDoctor Payments Data

Esther Aoigan, MD

Family Medicine · Southfield, MINPI 1588654776

Payments from drug & device makers

$546in general payments, 2019–2025

Across 19 payments — averaging $28.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$179
  • AstraZeneca$121
  • Novo Nordisk$120
  • Sumitomo Pharma America, Inc.$47
  • Neurocrine Biosciences, Inc.$40
  • Biohaven Pharmaceutical Holding Company Ltd.$23
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$119,218
Medicare patients
192
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$78,223
Invega SustennaPaliperidone Palmitate12$42,497
JardianceEmpagliflozin45$29,198
JanuviaSitagliptin Phosphate30$22,051
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,997
XareltoRivaroxaban32$17,690
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen624$16,072
Diclofenac Sodium102$15,964
EntrestoSacubitril/Valsartan18$11,697
GemtesaVibegron19$11,157
TradjentaLinagliptin17$9,665
BrilintaTicagrelor20$9,172
JanumetSitagliptin Phos/Metformin Hcl24$9,151
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$8,371
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$7,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Symbicort$121$15,79748 claims
Sumitomo Pharma America, Inc.Gemtesa$47$11,15719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →